©2024 Stanford Medicine
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)
Not Recruiting
Trial ID: NCT00250432,
Purpose
Comparison of the safety and effectiveness of standard drug dosing versus a daily dose 3
times higher than the standard dose in patients with invasive candidiasis (bloodstream and/or
systemic yeast infections)
Official Title
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults
Stanford Investigator(s)
Dora Ho
Clinical Professor, Medicine - Infectious Diseases
Eligibility
Inclusion Criteria:
- Clinical and Laboratory evidence of blood stream &/or systemic candida infections
Exclusion Criteria:
- Possible candida contamination
- Candida colonization (non invasive infection), urine, cardiac, bone or brain and
prosthetic device infections
- Acute or moderately severe liver disease
- Abnormal liver function tests
- Abnormal blood clotting for patients on blood thinners
Intervention(s):
drug: caspofungin acetate
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Joanna Schaenman